XML 53 R41.htm IDEA: XBRL DOCUMENT v3.21.2
REVENUE (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Disaggregation of Revenue [Line Items]        
Total net product sales $ 127,722 $ 117,484 $ 382,339 $ 298,673
EXPAREL / bupivacaine liposome injectable suspension        
Disaggregation of Revenue [Line Items]        
Total net product sales 122,609 114,163 369,128 290,459
iovera°        
Disaggregation of Revenue [Line Items]        
Total net product sales 4,182 2,726 11,264 6,391
Total net product sales        
Disaggregation of Revenue [Line Items]        
Total net product sales $ 126,791 $ 116,889 380,392 $ 296,850
European Union or E.U. | EXPAREL / bupivacaine liposome injectable suspension        
Disaggregation of Revenue [Line Items]        
Total net product sales     0  
European Union or E.U. | iovera°        
Disaggregation of Revenue [Line Items]        
Total net product sales     $ 0  
Minimum        
Disaggregation of Revenue [Line Items]        
Accounts receivable, payment terms     0 days  
Maximum        
Disaggregation of Revenue [Line Items]        
Accounts receivable, payment terms     37 days